FDA Oncology Center of Excellence

FDA Oncology Center of Excellence
Name	FDA Oncology Center of Excellence
Formation	2017
Headquarters	Silver Spring, Maryland
Parent organization	Food and Drug Administration
Leader title	Director
Leader name	(see Organization and Leadership)
Website	(omitted)

FDA Oncology Center of Excellence

The FDA Oncology Center of Excellence is a specialized initiative within the Food and Drug Administration created to coordinate regulatory science, review, and policy for oncology products across multiple FDA centers. It serves as a focal point linking reviewers, researchers, and policy makers to accelerate development and patient access to cancer therapies while harmonizing review standards across therapeutic, biologic, diagnostic, and radiological modalities. The Center interacts with a range of stakeholders including industry sponsors, patient advocacy organizations, academic cancer centers, and international regulators.

Overview

The Center was established to unify expertise from the Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health, and other FDA components such as the Office of Regulatory Affairs and the National Cancer Institute. It aims to streamline reviews for small molecules, monoclonal antibodies, cell and gene therapies, and companion diagnostics developed by sponsors like Pfizer, Roche, Merck & Co., Novartis, and Bristol-Myers Squibb. The Center emphasizes adaptive regulatory tools seen in programs such as the Breakthrough Therapy designation, Accelerated Approval, Priority Review, and initiatives parallel to those used by regulators like the European Medicines Agency and the Medicines and Healthcare products Regulatory Agency.

History and Establishment

The concept emerged amid growing regulatory complexity as oncology products moved from cytotoxic chemotherapies to targeted therapies, immunotherapies, and precision diagnostics developed at institutions like Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and MD Anderson Cancer Center. Announced during the administration of Donald Trump and formalized in 2017, the Center built on precedents including the FDA’s oncology office structures and collaborative projects with the National Institutes of Health and the National Cancer Institute. Its creation paralleled policy shifts such as the 21st Century Cures Act and global harmonization efforts like the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.

Organization and Leadership

Leadership has drawn on senior officials with backgrounds in oncology regulatory science, clinical practice, and pharmaceutical development, interacting with advisory bodies such as the Oncologic Drugs Advisory Committee and the Pediatrics Advisory Committee. The Center coordinates cross-center review teams including medical officers, statisticians, pharmacologists, and regulatory project managers, and interfaces with external stakeholders like the American Society of Clinical Oncology, American Association for Cancer Research, and patient groups such as Susan G. Komen and the Leukemia & Lymphoma Society. Executive leadership reports to senior FDA leadership structures associated with the Commissioner of Food and Drugs and engages with legislative oversight by committees including the United States Senate Committee on Health, Education, Labor, and Pensions and the United States House Committee on Energy and Commerce.

Regulatory Activities and Initiatives

The Center coordinates novel regulatory pathways and encourages the use of biomarkers and novel endpoints, aligning with guidance documents and programs such as Real-World Evidence, the NCI-MATCH trial framework, and master protocols like those developed by EORTC and the Adaptive Platform Trials Coalition. It supports development of companion diagnostics in collaboration with stakeholders including Foundation Medicine and Thermo Fisher Scientific and evaluates cell and gene therapies from sponsors including Bluebird Bio and Gilead Sciences. The Center has been involved in reviewing approvals tied to pivotal trials conducted at academic networks such as ALLIANCE and cooperative groups like the Children's Oncology Group, and in shaping policy on postmarketing commitments and risk evaluation frameworks exemplified by Risk Evaluation and Mitigation Strategies.

Research, Collaboration, and Innovation

The Center fosters collaborative research partnerships with the National Cancer Institute, academic consortia like SWOG Cancer Research Network, and international regulators including the Pharmaceuticals and Medical Devices Agency. It promotes use of biomarkers such as PD-L1, EGFR, ALK, and genomic profiling platforms from Broad Institute collaborators, and encourages incorporation of digital health tools developed by firms like Flatiron Health and Tempus. Initiatives include methodological work on master protocols, decentralized trials seen in response to crises like the COVID-19 pandemic, and modeling efforts that draw on real-world oncology datasets and artificial intelligence approaches used by organizations such as Google Health and IBM Watson Health.

Impact and Criticism

The Center has been credited with expediting approvals for therapies including targeted inhibitors and immune checkpoint inhibitors originating from companies like AstraZeneca and Bayer, and with advancing use of novel endpoints in oncology development. Critics raise concerns about accelerated pathways’ reliance on surrogate endpoints, citing high-profile debates around approvals linked to surrogate measures and withdrawals involving products from sponsors such as Johnson & Johnson. Observers from patient advocacy organizations and academic critics at universities including Harvard University and Yale University have called for greater transparency, stronger postmarketing evidence requirements, and clearer communication about benefit–risk trade-offs. Regulatory scholars reference tensions similar to those in the debates surrounding the Accelerated Approval pathway and the balance between timely access and evidentiary rigor.

Category:United States Food and Drug Administration